Susan Li

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

Karim Fizazi, NamPhuong Tran, Luis Fein et al. · The Lancet Oncology · 2019 · 813 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Kenneth J. Pienta, Jean-Pascal Machiels, Dirk Schrijvers et al. · Investigational New Drugs · 2012 · 399 citations

Medicine, Oncology, Pharmacology +17

Apalutamide and Overall Survival in Prostate Cancer

Matthew R. Smith, Fred Saad, Simon Chowdhury et al. · European Urology · 2020 · 290 citations · Full text

Medicine, Oncology, Pharmacology +16

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial

Fred Saad, David Cella, Ethan Basch et al. · The Lancet Oncology · 2018 · 128 citations

Medicine, Oncology, Pharmacology +12

Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study

Nobuaki Matsubara, Kim N., Mustafa Özgüroğlu et al. · European Urology · 2019 · 127 citations

Medicine, Oncology, Urology +17